
Healthcare Technology KTN
Healthcare Technology KTN
1 Projects, page 1 of 1
assignment_turned_in Project2008 - 2018Partners:University of Leeds, Smith & Nephew plc (UK), CellTran Ltd, BITECIC Ltd, Technology Strategy Board +36 partnersUniversity of Leeds,Smith & Nephew plc (UK),CellTran Ltd,BITECIC Ltd,Technology Strategy Board,Xiros Plc,White Rose University Consortium,Tissue Science Laboratories (Uk) Ltd,Yorkshire Forward,Bitecic (United Kingdom),Medtronic (United Kingdom),Healthcare Technology KTN,Intercytex (United Kingdom),CellTran Ltd,NHS Blood and Transplant,Johnson & Johnson (United Kingdom),Gluco Ltd (Leeds Innovation Centre),DePuy Orthopaedics Inc,Axordia Ltd,Yorkshire Forward,White Rose University Consortium,Gluco Ltd (Leeds Innovation Centre),Smith & Nephew (United Kingdom),Smith & Nephew (United Kingdom),CellTran Ltd,Axordia Ltd,White Rose University Consortium,Pfizer (United Kingdom),University of Leeds,Axordia Ltd,Yorkshire Forward,White Rose University Consortium,ICX,National Blood Service,National Blood Service,DePuy Orthopaedics Inc,BITECIC Ltd,National Blood Service,Gluco Ltd (Leeds Innovation Centre),Xiros (United Kingdom),ICXFunder: UK Research and Innovation Project Code: EP/F500513/1Funder Contribution: 7,073,460 GBPDefinition: A rapidly developing area at the interfaces of engineering/physical sciences, life sciences and medicine. Includes:- cell therapies (including stem cells), three dimensional cell/ matrix constructs, bioactive scaffolds, regenerative devices, in vitro tissue models for drug discovery and pre-clinical research.Social and economic needs include:Increased longevity of the ageing population with expectations of an active lifestyle and government requirements for a longer working life.Need to reduce healthcare costs, shorten hospital stays and achieve more rapid rehabilitationAn emergent disruptive industrial sector at the interface between pharmaceutical and medical devicesRequirement for relevant laboratory biological systems for screening and selection of drugs at theearly development stage, coupled with Reduction, Refinement, Replacement of in vivo testing. Translational barriers and industry needs: The tissue engineering/ regenerative medicine industry needs an increase in the number of trained multidisciplinary personnel to translate basic research, deliver new product developments, enhance manufacturing and processing capacity, to develop preclinical test methodologies and to develop standards and work within a dynamic regulatory environment. Evidence from N8 industry workshop on regenerative medicine.Academic needs: A rapidly emerging internationally competitive interdisciplinary area requiring new blood ---------------------
All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://beta.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=ukri________::2ce8c595ee4f6f83cb4e2732c36466d5&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eumore_vert All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://beta.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=ukri________::2ce8c595ee4f6f83cb4e2732c36466d5&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eu